Nyxoah Secures $27 Million Through Innovative Financing
Nyxoah SA, a pioneering medtech company focused on transforming the treatment landscape for obstructive sleep apnea (OSA), has recently announced a major financial milestone. The company successfully raised $27 million by selling 3.0 million shares through its at-the-market offering, targeting a price aligned with its current market value on the Nasdaq Global Market. This strategic move not only strengthens Nyxoah's balance sheet but also marks a significant step towards its expansion efforts, particularly in the U.S. market.
Investment Strategy and Future Focus
The investment was driven by substantial interest from a new healthcare investor based in the United States. Olivier Taelman, Nyxoah's Chief Executive Officer, emphasized how this funding solidifies their commitment to developing innovative treatments while honing in on the U.S. market. Taelman noted that the move aligns with the positive results from their DREAM pivotal study, presented at a significant surgical sleep congress, which reinforced the efficacy of their flagship product.
The Genio® System: A Game Changer
Nyxoah's core innovation, the Genio® system, represents a breakthrough as a battery-free hypoglossal neuromodulation device. It is carefully designed for flexibility, being inserted through a single incision below the chin and wirelessly controlled via a wearable device. This innovation not only simplifies the treatment for patients but also promises superior outcomes in reducing the burden of OSA.
Recent Regulatory Milestones
The Genio® device has seen swift progress in regulatory approvals, having received the European CE Mark in 2019 after the success of the BLAST OSA clinical study. In addition, Nyxoah has achieved further U.S. expansion through successful Initial Public Offerings (IPOs) on both Euronext Brussels and Nasdaq. The company is also anticipating positive FDA approval outcomes for their ongoing studies, including the recently concluded BETTER SLEEP study, which broadened their therapeutic efficacy to patients previously deemed contraindicated for alternate therapies.
Building a Strong Foundation for Growth
With the additional funds secured, Nyxoah is now well-positioned to prepare for the marketing launch of Genio® within the United States. The company's strategic direction aims to leverage recent advancements in clinical data to inform its efforts in gaining FDA approvals and establishing a robust foothold in the competitive market for obstructive sleep apnea treatments. Such developments underscore Nyxoah's dedication to not just growth, but impactful contributions to healthcare, particularly for the one billion individuals globally suffering from OSA.
Frequently Asked Questions
What is the purpose of Nyxoah's recent $27 million fundraising?
The funds aim to strengthen Nyxoah's financial position and support the U.S. launch of its Genio® device.
How does the Genio® system work?
Genio® is a battery-free hypoglossal neuromodulation device controlled by a wearable, intended to treat obstructive sleep apnea.
What regulatory approvals has Nyxoah obtained for Genio®?
Genio® received the European CE Mark in 2019 and is undergoing processes for FDA approval in the U.S. market.
Who invested in Nyxoah's latest offering?
A new U.S.-based healthcare investor acquired the shares sold in the recent at-the-market offering.
What is Nyxoah's focus moving forward?
Nyxoah is focused on expanding its market presence in the U.S. and advancing its innovative treatment options for obstructive sleep apnea.
